Literature DB >> 29574651

D-dimer predicts postoperative recurrence and prognosis in patients with liver metastasis of colorectal cancer.

Akira Watanabe1, Kenichiro Araki2, Norihumi Harimoto2, Norio Kubo2, Takamichi Igarashi2, Norihiro Ishii2, Takahiro Yamanaka2, Kei Hagiwara2, Hiroyuki Kuwano3, Ken Shirabe2.   

Abstract

BACKGROUND: Colorectal cancer is common, and its incidence is increasing throughout the world. The liver is a major metastatic site, and colorectal liver metastasis (CRLM) has a poor prognosis. Although liver resection is the most effective therapy for CRLM, postoperative recurrence is common. Thus, prognostic markers for CRLM are greatly needed. D-dimer, a fibrin cleavage product, has been shown to be related to colorectal tumor progression, and is also associated with malignant progression and recurrence in various cancers. Therefore, we evaluated the value of D-dimer in predicting the prognosis in CRLM.
METHODS: We retrospectively evaluated 90 cases of resected CRLM to determine the correlation between D-dimer and patient survival. The cut-off value for D-dimer levels was determined using receiver operating characteristic curve analysis.
RESULTS: Significant differences occurred in the recurrence group with higher D-dimer levels (P = 0.00736*), while the optimal cut-off value was 0.6 µg/mL. High D-dimer levels (≥ 0.6 µg/mL) were associated with poor recurrence-free survival (RFS; P = 0.0000841*) and cancer-specific survival (CSS; P = 0.00615*). In the multivariate analysis, D-dimer correlated with CRLM prognosis and independently predicted RFS (P = 0.0179*).
CONCLUSION: High D-dimer levels were associated with poor RFS and CSS. D-dimer was an independent prognostic factor of RFS. Therefore, D-dimer may help predict recurrence and prognosis in patients with CRLM.

Entities:  

Keywords:  Colorectal cancer; D-dimer; Liver metastasis

Mesh:

Substances:

Year:  2018        PMID: 29574651     DOI: 10.1007/s10147-018-1271-x

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  38 in total

1.  Prognostic value of preoperative D-dimer and carcinoembryonic antigen levels in patients undergoing intended curative resection for colorectal cancer: a prospective cohort study.

Authors:  Ehsan Motavaf; Kåre Gotschalck Sunesen; Mogens Tornby Stender; Ole Thorlacius-Ussing
Journal:  Int J Colorectal Dis       Date:  2014-08-23       Impact factor: 2.571

Review 2.  Different treatment strategies and molecular features between right-sided and left-sided colon cancers.

Authors:  Hong Shen; Jiao Yang; Qing Huang; Meng-Jie Jiang; Yi-Nuo Tan; Jian-Fei Fu; Li-Zhen Zhu; Xue-Feng Fang; Ying Yuan
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

3.  Increases in quantitative D-dimer levels correlate with progressive disease better than circulating tumor cell counts in patients with refractory prostate cancer.

Authors:  Joseph D Khoury; Dorothy M Adcock; Fanny Chan; James T Symanowski; Stefan Tiefenbacher; Oscar Goodman; Lazara Paz; Yupo Ma; David C Ward; Nicholas J Vogelzang; Louis M Fink
Journal:  Am J Clin Pathol       Date:  2010-12       Impact factor: 2.493

4.  Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer.

Authors:  Frederiek F van Doormaal; Marcello Di Nisio; Hans-Martin Otten; Dick J Richel; Martin Prins; Harry R Buller
Journal:  J Clin Oncol       Date:  2011-04-18       Impact factor: 44.544

5.  Primary tumor location as a prognostic factor in metastatic colorectal cancer.

Authors:  Fotios Loupakis; Dongyun Yang; Linda Yau; Shibao Feng; Chiara Cremolini; Wu Zhang; Martin K H Maus; Carlotta Antoniotti; Christiane Langer; Stefan J Scherer; Thomas Müller; Herbert I Hurwitz; Leonard Saltz; Alfredo Falcone; Heinz-Josef Lenz
Journal:  J Natl Cancer Inst       Date:  2015-02-24       Impact factor: 13.506

6.  The effect of low molecular weight heparin on survival in patients with advanced malignancy.

Authors:  Clara P W Klerk; Susanne M Smorenburg; Hans-Martin Otten; Anthonie W A Lensing; Martin H Prins; Franco Piovella; Paolo Prandoni; Monique M E M Bos; Dick J Richel; Geertjan van Tienhoven; Harry R Büller
Journal:  J Clin Oncol       Date:  2005-02-07       Impact factor: 44.544

Review 7.  Anticoagulants versus cancer.

Authors:  Chris Tieken; Henri H Versteeg
Journal:  Thromb Res       Date:  2016-04       Impact factor: 3.944

8.  High plasma D-dimer level is associated with decreased survival in patients with lung cancer: a meta-analysis.

Authors:  Yong-Xin Zhou; Zhong-Min Yang; Jing Feng; Ying-Jun Shan; Wei-Li Wang; Yun-Qing Mei
Journal:  Tumour Biol       Date:  2013-07-20

9.  Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma.

Authors:  Graham J Caine; Gregory Y H Lip; Paul S Stonelake; Peter Ryan; Andrew D Blann
Journal:  Thromb Haemost       Date:  2004-07       Impact factor: 5.249

10.  Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer.

Authors:  Ren Zhao; Zhen Cai; Sheng Li; Yong Cheng; Hua Gao; Fang Liu; Shiyang Wu; Suyan Liu; Yan Dong; Lei Zheng; Wenbin Zhang; Xiaojun Wu; Xueqing Yao
Journal:  Oncotarget       Date:  2017-02-07
View more
  11 in total

1.  Symptomatic aneurysmal bone cysts of the spine: clinical features, surgical outcomes, and prognostic factors.

Authors:  Yuechao Zhao; Shaohui He; Haitao Sun; Xiaopan Cai; Xin Gao; Peng Wang; Haifeng Wei; Wei Xu; Jianru Xiao
Journal:  Eur Spine J       Date:  2019-03-05       Impact factor: 3.134

2.  Haemostatic biomarkers for prognosis and prediction of therapy response in patients with metastatic colorectal cancer.

Authors:  Florian Moik; Florian Posch; Ella Grilz; Werner Scheithauer; Ingrid Pabinger; Gerald Prager; Cihan Ay
Journal:  Thromb Res       Date:  2020-01-07       Impact factor: 3.944

3.  High pretreatment plasma D-dimer levels predict poor prognosis in gastrointestinal cancers: A meta-analysis.

Authors:  Guoyi Rong; Wenxin Fan; Jian Shen
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

4.  The Plasma Concentration of D-Dimer is Associated with Neoadjuvant-Chemotherapy Efficacy and the Prognosis in Osteosarcoma.

Authors:  Yujing Huang; Zan Shen; Yang Yao; Aina He; Daliu Min
Journal:  Onco Targets Ther       Date:  2021-01-11       Impact factor: 4.147

5.  Clinical Significance of Preoperative Fibrinogen to Albumin Ratio in Patients with Glioblastoma: A Singe Center Experience.

Authors:  Junhong Li; Xingwang Zhou; Yufan Xiang; Shuxin Zhang; Wentao Feng; Yunbo Yuan; Yanhui Liu; Senlin Yin
Journal:  Cancer Manag Res       Date:  2021-04-14       Impact factor: 3.989

6.  Significance of preoperative blood tests in the prognosis of colorectal cancer: A prospective, multicenter study from Hungary.

Authors:  Adrienn Biró; Péter Kolozsi; Attila Nagy; Zsolt Varga; Zsolt Káposztás; Dezső Tóth
Journal:  J Clin Lab Anal       Date:  2021-11-23       Impact factor: 2.352

7.  Serology-Based Model for Personalized Epithelial Ovarian Cancer Risk Evaluation.

Authors:  Tianqing Yan; Xiaolu Ma; Haoyun Hu; Zhiyun Gong; Hui Zheng; Suhong Xie; Lin Guo; Renquan Lu
Journal:  Curr Oncol       Date:  2022-04-12       Impact factor: 3.109

8.  Clinical analysis of ultrasound-guided radiofrequency ablation for recurrent colorectal liver metastases after hepatectomy.

Authors:  Xiao-Xiang Fan; Shu-Yi Lv; Mei-Wu Zhang; Xiao-Yu Dai; Jian-Pei Zhao; Da-Feng Mao; Yan Zhang
Journal:  World J Surg Oncol       Date:  2020-04-20       Impact factor: 3.253

9.  Fibrinogen/albumin ratio as a promising predictor of platinum response and survival in ovarian clear cell carcinoma.

Authors:  Wei Chen; Boer Shan; Shuling Zhou; Huijuan Yang; Shuang Ye
Journal:  BMC Cancer       Date:  2022-01-21       Impact factor: 4.430

10.  D-Dimer level was associated with prognosis in metastatic colorectal cancer: A Chinese patients based cohort study.

Authors:  Chan Liu; Yueguo Ning; Xiaoming Chen; Qian Zhu
Journal:  Medicine (Baltimore)       Date:  2020-02       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.